Phase 2 biotech developing an in-licensed therapy for cardiorenal disorders.
Industry: Health Care
Latest Trade: $13.50 0.00 (0.0%)
First Day Return: +15.3%
Return from IPO: -15.6%
Industry: Health Care
IPO Data | |
---|---|
IPO File Date | 01/18/2023 |
Offer Price | $16.00 |
Price Range $14.00 - $16.00 | |
Offer Shares (mm) | 12.0 |
Deal Size ($mm) | $192 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
IPO Data | |
---|---|
IPO Date | 02/09/2023 |
Offer Price | $16.00 |
Price Range $14.00 - $16.00 | |
Offer Shares (mm) | 12.0 |
Deal Size ($mm) | $192 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
Underwriters |
---|
BofA Securities |
Evercore ISI |
more |
Company Data | |
---|---|
Headquarters | Radnor, PA, United States |
Founded | 2019 |
Employees at IPO | 12 |
Website www.mineralystx.com |